Natural MedTech

Natural MedTech, a biotechnology company established in 2021, is focused on the development and manufacturing of psychedelic compounds for therapeutic applications. The firm operates within the emerging market of psychedelic medicine, aiming to supply research institutions, pharmaceutical companies, and clinical trials with high-quality, naturally derived psilocybin and other psychedelic substances. The company's business model is centered on being a key supplier of active pharmaceutical ingredients (APIs) derived from biological sources, positioning itself as a crucial component of the supply chain for psychedelic research and drug development. Revenue is generated through the sale of these cGMP (Current Good Manufacturing Practice) compliant psychedelic compounds to its client base.

The company was co-founded by Jesse Cilliers, who serves as the Chief Executive Officer, and Joshua Bub, the Chief Operating Officer. Jesse Cilliers brings a background in commercial finance and corporate advisory, with experience advising on M&A and capital raises for life-science and technology companies. This financial expertise is applied to steer the company's strategic growth and funding initiatives. Joshua Bub's professional history includes roles in strategy, operations, and corporate development across various sectors, including pharmaceuticals. His experience contributes to establishing the company's operational and manufacturing capabilities. The founding team's combined background in finance, corporate strategy, and the life sciences sector underpins their approach to building a vertically integrated psychedelic medicine business.

Natural MedTech's core offering is the production of naturally derived psilocybin, which they cultivate and process in their facilities. The company has secured the necessary licenses from the Australian Office of Drug Control to legally cultivate and manufacture psilocybin mushrooms for research purposes. A key differentiator is their focus on natural sources, as opposed to synthetically produced compounds, and their development of a proprietary process that results in a powdered, full-spectrum psilocybin product. This product contains not only psilocybin but also other potentially therapeutic compounds found in the mushrooms, such as baeocystin and norbaeocystin, which may offer a different therapeutic profile compared to synthetic alternatives. By achieving cGMP certification for their manufacturing processes, Natural MedTech ensures its products meet the stringent quality and consistency standards required for clinical and pharmaceutical use.

Keywords: psychedelic medicine, psilocybin manufacturing, biotechnology, pharmaceutical ingredients, mental health treatment, natural compounds, cGMP, drug development, clinical trial supply, neurotherapeutics